Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Cyclobenzaprine hydrochloride very low dose - Tonix Pharmaceuticals

Drug Profile

Cyclobenzaprine hydrochloride very low dose - Tonix Pharmaceuticals

Alternative Names: Cyclobenzaprine HCL; Cyclobenzaprine hydrochloride - Tonix Pharmaceuticals; KRL-102; TNX-102; TNX-102 SL; Tonmya; VLD-cyclobenzaprine

Latest Information Update: 12 May 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Vela Pharmaceuticals
  • Developer Tonix Pharmaceuticals Holding Corp; Tonix Pharmaceuticals Inc
  • Class Amines; Analgesics; Anxiolytics; Behavioural disorder therapies; Dibenzocycloheptenes; Drug withdrawal therapies; Muscle relaxants; Small molecules
  • Mechanism of Action Alpha 1 adrenergic receptor antagonists; Histamine H1 receptor antagonists; Muscarinic M1 receptor antagonists; Serotonin 2A receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase III Fibromyalgia; Post-traumatic stress disorders
  • Phase II Agitation; Post acute COVID 19 syndrome
  • Preclinical Alcoholism
  • No development reported Unspecified

Most Recent Events

  • 12 May 2023 Tonix Pharmaceuticals announces intention to submit NDA to US FDA for Fibromyalgia
  • 06 Apr 2023 Tonix Pharmaceuticals completes enrolment in its phase-II clinical trials in Post-acute-COVID-19-syndrome in USA (Sublingual) (NCT05472090)
  • 13 Mar 2023 Tonix Pharmaceuticals has patent pendings covering for "Methods of Treating Acute Stress Disorder and Posttraumatic Stress Disorder" in Gulf cooperation, Taiwan, USA, Malaysia, New Zealand, Brazil, Canada, China, Europe, Hong Kong, India, Indonesia, Israel, Japan, Mexico, Singapore and South Africa
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with a username/password associated to your organization’s account.
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Federated access using single sign-on credentials.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top